ATARA BIOTHERAPEUTICS, INC. : Completion of Acquisition or Disposal of Assets, Financial Statements and Exhibits (Form 8-K)

By Donald M. Blake Last updated Apr 4, 2022

Item 2.01 Completion of Acquisition or Disposal of Assets

As stated earlier, on January 26, 2022, Atara Biotherapeutics, Inc.a
Delaware company (the “Company”), has entered into an asset purchase agreement (the “Asset Purchase Agreement” and the transactions contemplated therein, the “Transaction”) by and between the Company, FUJIFILM Diosynth Biotechnologies California, Inc.(“FUJIFILM”), and for certain limited purposes, FUJIFILM Holdings America Corporationproviding for the sale to FUJIFILM of certain rights and assets related to the Atara T-Cell Operations and Manufacturing plant located in 2430 Conejo Spectrum Street, Thousand Oaks, California (the “Transferred Assets”). At April 4, 2022 (the “Closing”), the Company has completed the Transaction and the sale of the Transferred Assets and has received aggregate consideration of approximately $100 millionsubject to any post-closing purchase price adjustments.

The above summaries of the Asset Purchase Agreement and contemplated transactions do not purport to be complete and are subject to and qualified in their entirety by the full text of the Asset Purchase Agreement. A copy of the Asset Purchase Agreement is attached hereto as Schedule 2.1 and is incorporated herein by reference.

Item 9.01 Financial statements and supporting documents


(d) Exhibits

Exhibit
  No.                                     Description

  2.1          Asset Purchase Agreement, dated as of January 26, 2022, by and
             between Atara Biotherapeutics, Inc., FUJIFILM Diosynth Biotechnologies
             California, Inc., and for certain limited purposes, FUJIFILM Holdings
             America Corporation*

  104        Cover Page Interactive Data File (embedded within the Inline XBRL
             document)

* Portions of this exhibit have been omitted because (i) they are not material; and

(ii) would likely cause harm to competition if made public.

————————————————– ——————————